A study by researchers at the University of Colorado Cancer Center is evaluating an imaging method that can help protect normal, healthy lung tissue during radiotherapy treatment in lung cancer patients.
A collaborative study, initiated by researchers at the University of Colorado Cancer Center, is evaluating an imaging method that can help protect normal, healthy lung tissue during radiotherapy treatment in lung cancer patients.
Using advanced image analysis techniques, the scientists plan to use results from 4D CT scans to map areas of the lung that have retained normal function without the need for additional testing. According to investigator Yevgeniy Vinogradskiy, PhD, lead investigator and assistant professor in the Department of Radiation Oncology at the CU School of Medicine, “We used to treat the lungs as a homogenous organ, as if all areas were equally important. Now we know that's not true - there's regionally variant function. The idea of this clinical trial is to spare functional portions of the lung during radiation by using this new imaging modality to display lung function.”
The complication arises from the fact that lung tumors move with every single breath that patients make, which makes a static image clicked at a specific time a crude estimate of the tumor’s position. The 4D CT, on the other hand, clicks a series of images shot over time to capture images of the lung and the tumor at different phases of the patient’s breathing cycle. Using the “lung function” information, which is information on the functional lung tissue around the tumor, physicians can carefully target the radiation so the normal tissue is spared during the process. The ultimate objective is to improve the patient’s quality of life.
The most important advantage, according to Vinogradskiy, is that there’s no additional testing required. The researchers will use existing imaging data acquired as part of standard of care. The trial will enroll 70 patients and is expected to be completed in 3 years.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More